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Abstract
Chordomas and chondrosarcomas are rare tumors that commonly experience loco-regional
recurrence after primary treatment, making management of these tumors complex and difficult.
Published case series reporting post-surgical outcomes for chordoma indicate that loco-regional
recurrence affects more than 50% of patients treated with macroscopic complete resection with or
without RT. Notably, a high proportion of recurrences occur late (after 5 and 10 years), requiring
long-term follow-up. Chordomas and chondrosarcomas are considered to be radioresistant and
require high doses of radiation greater than 60 Gy (Catanzano et al., 2019). There is a little data
available regarding the most effective way to minimize dose to the spinal cord when treating
chordoma and chondrosarcoma patients. Seven patients that were previously treated for chordoma
or chondrosarcoma at our institution utilizing conventional VMAT optimization techniques were
replanned using the jaw-blocking technique. Plans were generated in Raystation 11A for a 2.5mm
leaf Truebeam linear accelerator. Comparisons were made using the relative reduction in the dose
indices for the spinal cord. The dose metrics analyzed were the maximum dose, dose to 0.1cc, and
mean dose. Additionally, comparisons were made for the GTV, CTV, and PTV coverage for each
plan. The results showed statistically significant reduction is max, mean, and dose to 0.1cc of the
spinal cord and overall better coverage to target volumes. Using the jaw-blocking VMAT
technique is an effective treatment technique when the goal is to minimize as much dose to the
spinal cord as possible.

Introduction
Chordomas and chondrosarcomas are rare malignant bone tumors, which share several
characteristics, but each have their own distinctive features. Both tumors produce an abundant
extracellular matrix, which contributes to their histological identification. Chordomas and
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chondrosarcomas both express several proteins known to be important in the cartilage matrix
production including aggrecan, Type II collagen, cartilage oligometric matrix protein and SOX-9
(Schwab et al., 2008). Chordomas and chondrosarcomas are often considered together because of
their similar clinical presentation, sites of occurrence, radiographic appearance, and surgical
management. The two, however, are distinct pathological entities, with different origins and
pathogenesis (Pamir et al., 2017).
Chordomas and chondrosarcomas are locally invasive with high recurrence rates after
surgery. Gross total resection is the current treatment of choice for both chordomas and
chondrosarcomas. Because these tumors often invade local tissue and their close proximity to
critical structures, an en bloc resection is possible only for a minority of patients. Radiation
therapy can improve local control and overall survival but because these tumors have been
historically classified as radio resistant, high-dose radiation, typically exceeding 60 Gy, offers the
best chance at local control (Indelicato et al., 2016). Radiation oncologists face similar challenges
when delivering a sufficient dose to eliminate the tumor while preserving the function of the doselimiting normal tissues/organs such as the spinal cord, nerve roots, cranial nerves, and brainstem.
While the traditionally accepted dose to the spinal cord is 45-50 Gy, these doses are not adequate
for local control of chordomas and chondrosarcomas. Doses less than 60 Gy have historically led
to poor outcomes with recurrence rates as high as 70-100% after conventional photon radiation
therapy (De Amorim Berstein & DeLaney, 2016).
Proton therapy is often the treatment of choice for these types of tumor since the required
high doses for tumor control cannot be achieved using conventional radiotherapy due to the dose
limits of the spinal cord. These patients often have titanium orthopedic hardware near the tumor
site to stabilize the vertebral column after surgical resection. Implanted materials can affect the
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accuracy of proton therapy treatment plans due to metal artifacts in the computed tomography
scans and the approximations of pencil-beam dose calculation methods (Verberg et al.,2013). Due
to the uncertainty associated with metal artifacts in relation to proton planning, patients are
typically treated with a combination of photon and protons with promising rates of local control.
Chordoma
Chordomas represent less than 1% of intracranial tumors and 3% of primary bone tumors,
with an incidence of 0.08 per 100,000, peaking in the sixth decade, with a 2:1 male predominance.

Chordomas originate from embryological remnants of the notochord known as

ecchordoses, found within the bony craniospinal axis. Clinically, chordomas concentrate around
the clivus and craniocervical junction (32%) and the sacrococcygeal region (29%), with remainder
distributed along the rest of the spinal axis (33%). Although classified as a low-grade tumor,
chordomas are associated with high morbidity and mortality and frequent local recurrence with
invasion of surrounding tissues (Pamir et al.,2017).
Chondrosarcoma
According to the World Health Organization, chondrosarcomas represent a heterogeneous
group of tumors characterized by their ability of cartilage formation. Chondrosarcoma is the third
most common primary malignant bone tumor after osteosarcoma and Ewing’s sarcoma. However,
the incidence of spinal chondrosarcomas is estimated to be from 2% to 12% in various series. The
thoracic spine is the most frequent localization, followed by the cervical and lumbar region. Unlike
most other malignant spinal tumors, the lesions may arise in the vertebral body (5%), the posterior
elements (40%), or both (45%), since there are three growth centers in each vertebra from which
the tumor originates (Katonis et al., 2011). Annual incidence of chondrosarcoma is estimated to
be 1 in 200,000. Chondrosarcomas are twice as common in males as females and the age
distribution varies based on histological subtype; however, there is a peak in incidence during the
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5th and 6th decades of life (Blumstein et al., 2020). Given the low incidence of these tumors and
the presumption of radioresistance by some clinicians, there are limited studies of large cohorts to
evaluate the effect of radiotherapy on survival outcomes in chondrosarcoma patients (Catanzano
et al., 2019).
Advances in radiation therapy technology have allowed for the delivery of higher doses of
radiation with sharp dose gradients. Dial et al analyzed data from the National Cancer database
on 1478 chordoma of the skull base (n=567), mobile spine (n=360), and sacrum (n=551) that were
treated between 2004 and 2015 with conventional radiation therapy. Patients were grouped by
treatment modality: 3D EBRT, SRS, IMRT, and PBT. For patients receiving RT, the modality of
therapy was available for 682 patients. Conventional external beam radiation (EBRT) was utilized
in 250 (36.7%) patients and advanced techniques were used in 432 (63.3%). The advanced
techniques included PBT (n = 189), IMRT (n = 143), or SRS (n = 100). The highest 5-year survival
rate was seen in the advanced RT group (81.2%; 95% CI: 76-85%) followed by SRS (74.9%; 95%
CI: 64-83%) and conventional (68.2%; 95% CI: 61-75%) with survival rates for both the advanced
(P < .001) and SRS (P=0.003) significantly higher than conventional RT. The survival rate for
patients receiving PBT (P < .001), SRS (P = 0.006), or IMRT (P = 0.011) were all statistically
higher compared with EBRT, but not statistically different amongst themselves. The total dose of
RT was analyzed for 599 patients; the dose was palliative (< 40 Gy) in 75 patients, low dose (4065 Gy) in 226 patients, and high dose (> 65 Gy) in 218 patients. The high dose radiation group
had significantly improved overall survival rates compared with the low dose radiation group (P <
0.001) with 5-year survival rates of (85.1%; CI 95%: 79-90%) and (69.3%; 95% CI: 61-76%)
respectively (Dial et al., 2020).
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In another study, Hug et al reported on the results of combined proton and photon radiation
therapy for tumors in the axial skeleton and spine at MGH/Harvard Cyclotron laboratories.
Between December 1980 and September 1992, 20 patients were treated for primary or recurrent
chordomas (14) and chondrosarcomas (6) of the spine. The total target dose ranged from 67.1
CGE to 82.0 CGE (mean 74.6 CGE) for the chordoma patients. Five of the 14 patients failed
locally: four within the radiation field and one patients outside of the treatment portal but within
the operative site. One out of the four patients with gross total tumor resection failed locally vs
three out of eight patients with subtotal resection. Two patients were relapse free. The five local
failures occurred among the 11 patients receiving less than 77 CGE target dose. In contrast to the
chordoma patients, all six patients that were treated for chondrosarcoma remained locally
controlled. Four patients were irradiated postoperatively with total doses between 75.6 and 75.1
CGE (Hug et al., 1995).

Methods and Materials
Patient Selection
This retrospective, institutional review board-approved study evaluated 7 patients with
pathologically proven chordoma or chondrosarcoma that were previously treated at a single South
East institution between 2016 and 2021 using either IMRT, VMAT, or a combination of IMRT or
VMAT and proton. Since the primary goal of the study was to evaluate the effectiveness of
lowering the dose to the spinal cord, patients selected may have had prior radiation and tumors
could be primary of locally recurring after surgery. Refer to Table 1 for a summary of patient
characteristics. Patients ranged in age from 32 – 70 years (mean 47.3 years). Since the dose
limiting structure for patients with tumors in the clivus is the brainstem and typically have less
spinal cord involvement, patients with these types of tumors were excluded from the study. Sacral
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chordoma cases were excluded as well since tumor involvement generally involves the cauda
equine versus the spinal cord.
All patients were simulated with and without contrast on a Philips CT scanner in 1 mm
slice thickness, scans were reconstructed utilizing the O-MAR metal artifact reduction algorithm
to minimize artifact from spine stabilizing hardware. Patients were immobilized with a
thermoplastic mask and moldcare pillow on the BOS frame in the supine position with their arms
at their sides.
Planning
VMAT plans were generated by a single planner in Ray Station 11A SP1 for treatment on
the True Beam linear accelerator with HD leaves using 6MV photons. Plans were normalized the
same as the original plans for consistency, which varied between plans. Final dose calculations
were computed using the Collapsed Cone Algorithm. The physician contoured all OARs, planning
CT scans were fused with and with and without contrast MRI that was performed at an outside
facility. The gross tumor volume (GTV) is defined as the visible lesion on MRI; typically, this is
the contrast-enhancing lesion. The clinical target volume (CTV) is defined as the volume of tissue
that contains the GTV and any microscopic disease and potential paths of microscopic spread. The
PTV was created by expanding the CTV 5 mm (Combs et al., 2021). A PTVeval structure was
created for optimization by subtracting the spinal cord + 3mm from the PTV. Plans for cervical
spine cases were generated using 2 arcs, each arc split into 4 segments, avoiding entrance dose
through the oral cavity. Isocenter was placed in the center of the spinal cord and the spinal cord
was partially blocked by setting a jaw limit of -0.3 on the X2 jaw for beams that rotated clockwise
and 0.3 on the X1 jaw for fields that rotated in the counterclockwise direction. The position of the
collimator for each segment was determined by rotating halfway through the arc and turning the
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collimator to match the curvature of the spinal cord as close as possible. Patients with tumors in
the thoracic spine were treated with two full arcs, each arc split into three segements. Refer to
Figure 1 for a summary of gantry start and stop angles for patients treated in the cervical spine and
figure 2 for patients treated in the thoracic spine.
Since the purpose of this study was to evaluate the effectiveness of the jaw-blocking
VMAT technique, only PTV1 was evaluated to a dose of 50.4 Gy. PTV1 for patients that were
treated with a combination of VMAT and proton were treated in two phases. Phase one was treated
with photons to a dose of 23.4 Gy and the remaining 27 Gy treated with protons; therefore, plans
that were treated in this manner had the dose and objectives from the photon portion scaled to 50.4
Gy for comparison. To evaluate and compare the two plans, cumulative dose-volume histograms
(DVHs) were generated. To evaluate OAR sparing, DVH metrics for the spinal cord (Dmax,
D0.1cc) (see Figure 4), larynx (Dmean), pharyngeal constrictors (Dmean), oral cavity (Dmean),
esophagus (Dmean,), heart (Dmean,), and lungs (Dmean) were compared in their respective plans.

Results
The jaw-blocking VMAT plans were deemed clinically acceptable. The jaw-blocking
VMAT technique showed a reduction in dose to the spinal cord (max, mean, and dose to the 0.1cc)
in all seven of the presented cases; however, dose to surrounding OARs increased in most cases.
Spinal Cord
The maximum dose to the spinal cord was compared for both plans as well as the mean
spinal cord dose and dose to 0.1cc. Values for the maximum dose to the spinal cord on the original
plan ranged from 41.7 Gy to 50.6 Gy with a median dose of 44 Gy and mean spinal cord max dose
of 45.2 Gy. Values for the maximum dose to the spinal cord on jaw-blocking VMAT plan ranged
from 40 Gy to 41 Gy with a median dose of 41 Gy and mean spinal cord max dose of 40.7 Gy. A
8

Wilcoxon signed-rank test was performed and showed there was a statistically significant
difference between the max dose to the spinal cord between the two plans, with the max spinal
cord dose being significantly lower on jaw-blocking VMAT plans (n = 7, p = 0.018). Values for
the mean cord dose on the original plan ranged from 21.3 Gy to 34 Gy with a median dose of 33.8
Gy and a mean of 27.4 Gy. Values for the mean dose to the spinal cord on the jaw-blocking VMAT
plan ranged from 14.1 Gy to 19.7 Gy with a median dose of 17 Gy and mean dose of 16.6 Gy. A
Wilcoxon signed-rank test was performed and showed there was a statistically significant
difference between the mean dose to the spinal cord between the two plans, with the mean spinal
cord dose being significantly lower on the jaw-blocking VMAT plans (n = 7, p = 0.018). Values
for the dose to 0.1cc of the cord on the original plan ranged from 40.4 Gy to 48 Gy with a median
dose of 44.1 Gy and a mean of 43.7 Gy. Values for the dose to 0.1cc to the spinal cord on the
VMAT cord-blocking plan ranged from 35.5 Gy to 41 Gy with a median dose of 38.9 Gy and mean
dose of 38.1 Gy. A Wilcoxon signed-rank test was performed and showed there was a statistically
significant difference between the dose to 0.1cc of the spinal cord between the two plans, with the
dose to 0.1cc to the spinal cord being significantly lower on jaw-blocking VMAT plans (n = 7, p
= 0.018).
Esophagus
The mean dose to the esophagus was compared for both plans. Values for the mean dose
to the esophagus on the original plan ranged from 1.0 Gy to 25.2 Gy with a median dose of 19.7
Gy and mean dose of 13.8 Gy. Values for the mean dose to the esophagus on the jaw-blocking
VMAT plan ranged from 12.7 Gy to 25.1 Gy with a median dose of 16.4 Gy and mean esophagus
dose of 13.6 Gy. A Wilcoxon signed-rank test was performed and showed there was not a
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statistically significant difference in mean dose to the esophagus between the two plans (n = 5, p
= 0.5).
Oral Cavity
The mean dose to the oral cavity was compared for both plans. Values for the mean dose
to the oral cavity on the original plan ranged from 7.43 Gy to 25.2 Gy with a median dose of 19.7
Gy and mean dose of 13.8 Gy. Values for the mean dose to the oral cavity on the jaw-blocking
VMAT plan ranged from 12.7 Gy to 25.1 Gy with a median dose of 16.4 Gy and mean oral cavity
dose of 13.6 Gy. A Wilcoxon signed-rank test was performed and showed there was not a
statistically significant difference in mean dose to the oral cavity between the two plans (n = 5, p
= 0.5).
Bilateral Parotids
The mean dose to the bilateral parotids was compared for both plans. Values for the mean
dose to the parotids on the original plan ranged from 10.2 Gy to 25.2 Gy with a median dose of
19.7 Gy and mean dose of 13.8 Gy. Values for the mean dose to the parotids on jaw-blocking
VMAT ranged from 12.7 Gy to 25.1 Gy with a median dose of 16.4 Gy and mean bilateral parotid
dose of 13.6 Gy. A Wilcoxon signed-rank test was performed and showed that there was not a
statistically significant difference in mean dose to the bilateral parotids between the two plans (n
= 5, p = 0.686).
Larynx
The mean dose to the larynx was compared for both plans. Values for the mean dose to
the larynx on the original plan ranged from 10.2 Gy to 25.2 Gy with a median dose of 19.7 Gy and
mean dose of 13.8 Gy. Values for the mean dose to the larynx on the jaw-blocking VMAT plan
ranged from 12.7 Gy to 25.1 Gy with a median dose of 16.4 Gy and mean larynx dose of 13.6 Gy.
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A Wilcoxon signed-rank test was performed and showed that there was a statistically significant
difference between the mean dose to the larynx between the two plans, with the larynx dose being
higher on the jaw-blocking VMAT plans (n = 5, p = 0.043).
Mandible
The mean dose to the mandible was compared for both plans. Values for the mean dose to
the mandible on the original plan ranged from 7.6 Gy to 27 Gy with a median dose of 9.4 Gy and
mean dose of 12.3 Gy. Values for the mean dose to the mandible on the jaw-blocking VMAT plan
ranged from 12.7 Gy to 25.1 Gy with a median dose of 16.4 Gy and mean mandible dose of 13.6
Gy. A Wilcoxon signed-rank test was performed and showed there was not a statistically
significant difference in mean dose to the bilateral parotids between the two plans (n = 5, p =
0.893).
Pharyngeal Constrictors
The mean dose to the pharyngeal constrictors was compared for both plans. Values for the
mean dose to the pharyngeal constrictors on the original plan ranged from 23 Gy to 51.1 Gy with
a median dose of 37.6 Gy and mean dose of 31 Gy. Values for the mean dose to the pharyngeal
constrictors on the jaw-blocking VMAT plan ranged from 26.7 Gy to 50.6 Gy with a median dose
of 37.7 Gy and mean pharyngeal constrictor dose of 33.3 Gy. A Wilcoxon signed-rank test was
performed and showed there was not a statistically significant difference in mean dose to the
pharyngeal constrictors between the two plans (n = 5, p = 0.5).
Lungs
The mean dose to the lungs was compared for both plans on the two plans with involvement
in the thoracic spine. Values for the mean dose to the lungs on the original plan ranged from 10.2
Gy to 25.2 Gy with a median dose of 19.7 Gy and mean dose of 13.8 Gy. Values for the mean
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dose to the lungs on the jaw-blocking VMAT plan ranged from 12.7 Gy to 10.3 Gy with a median
dose of 16.4 Gy and mean lung dose of 13.6 Gy. A Wilcoxon signed-rank test was performed and
showed there was not a statistically significant difference in mean dose to the pharyngeal lungs
between the two plans (n = 2, p = 0.655).
Heart
The mean dose to the heart was compared for both plans on the two plans that involved the
thoracic spine. Values for the mean dose to the heart on the original plan ranged from 2.5 Gy to
10.3 Gy mean dose of 5.3 Gy. Values for the mean dose to the heart on jaw-blocking VMAT plan
ranged from 1.5 Gy to 17.6 Gy and mean heart dose of 8.9 Gy. A Wilcoxon signed-rank test was
performed and showed there was not a statistically significant difference in mean dose to the heart
between the two plans (n = 2, p = 0.655).
GTV, CTV, and PTV
Coverage to the GTV, CTV, and PTV were evaluated and compared for the two plans.
Coverage to the GTV (%) on the original plan ranged from 90.51 % to 99.96% with a median of
95.58% and a mean of 95.00%. Coverage to the GTV (%) on the jaw-blocking VMAT plan ranged
from 97.10 % to 99.97% with a median of 98.78% and a mean of 98.85%.

A Wilcoxon signed-

rank test was performed and showed there was a statistically significant difference the amount of
coverage to the GTV with the jaw-blocking VMAT plans providing better coverage to the GTV
(n =7 , p = 0.018). Coverage to the CTV (%) on the original plan ranged from 90.46% to 99.74%
with a median of 95.00 and a mean of 94.94%. Coverage to the CTV (%) on the jaw-blocking
VMAT plan ranged from 97.00 % to 99.29% with a median of 98.00% and a mean of 97.94%. A
Wilcoxon signed-rank test was performed and showed there was a statistically significant
difference in the amount of coverage to the CTV with the jaw-blocking VMAT plans providing
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better coverage to the CTV. (n =7 , p = 0.028). Coverage to the PTV (%) on the original plan
ranged from 72.4% to 95% with a median of 85.85%and a mean of 84.94%. Coverage to the PTV
(%) on the jaw-blocking VMAT plan ranged from 97.10 % to 99.97% with a median of 98.78%
and a mean of 98.85%. A Wilcoxon signed-rank test was performed and showed there was a
statistically significant difference in the amount of coverage to the PTV with the jaw-blocking
VMAT plans providing better coverage to the PTV. (n =7, p = 0.046).
The study showed that the jaw-blocking VMAT technique is effective at lower dose to the
spinal cord and while using this technique resulted in higher doses to some of the surrounding
OARs, only the mean dose to the larynx was statistically significant. The study also showed that
acceptable GTV, CTV, and PTV coverage was maintained when using the jaw-blocking VMAT
technique, and in all but one case, the coverage was higher on the jaw-blocking VMAT plan.

Discussion
There is little data available about the most effective way to minimize dose to the spinal
cord when treating chordoma and chondrosarcoma patients with VMAT. The purpose of the study
was to evaluate whether the jaw-blocking VMAT technique is an effective method in spinal cord
dose reduction. The data from the research showed that the VMAT cord blocking technique was
effective at lowering max dose to the spinal cord as well as significantly reducing the mean dose.
The spinal cord is a serial structure, as such; the maximum dose to the spinal cord is the most
important dose metric. Radiation-induced spinal cord injury is rare; however, myelopathy can be
severe resulting in pain, paresthesia, sensory deficits, paralysis, Brown-Sequard syndrome, and
even bowel/bladder incontinence. (Kirkpatrick et al., 2010). With conventional fractionation of 2
Gy per day including the full cord cross-section, a total dose of 50 Gy, 60 Gy, and ~69 Gy are
associated with a 0.2, 6, and 50% rate of myelopathy.
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The development of a secondary malignancy in the field of radiation is rare but wellrecognized hazard of cancer treatment. Even though the risk for developing a new tumor is low,
varying from 0.9% to 2%, the long survival time may present a considerable risk for the
development of a new tumor (Falacigna et al., 2016). Falacinga et al. presented a case study of a
30-year-old male that developed a pathologically confirmed radiation induced tumor in the L4
nerve root. The patient was treated 20 years prior for testicular seminoma to a total dose of 30.6
Gy irradiating the cervical and para-aortic regions. The implementation of treatment regimens
utilizing higher doses to the area surrounding the spinal cord may increase the risk of developing
a radiation-induced tumor to the spinal cord in the long term; therefore, the reduction in the mean
dose to the spinal cord may be an important metric to evaluate when treating to high doses.
Since the VMAT cord-blocking technique relies on a PTVeval structure that reduces the
portion of the PTV that is abutting the spinal cord by 3 mm, getting 95% of the PTV to be covered
by 100% of the dose is difficult. Chordomas and chondrosarcomas have a high rate of recurrence
with most cases most commonly recurring within the GTV. A study conducted by Noël et al
evaluated the survival and treatment complications in 67 consecutive patients that with treated
with fractionated photon and proton radiation for chordoma and chondrosarcoma. In two thirds of
the cases, relapses were located within the GTV (Noël et al., 2003). Due to the rate of relapse in
the GTV, the goal of the plan should be to get 100% of the GTV covered by 100% of the dose
when possible.
There were several limitations within the study. Since several of the plans had to have the
dose and objectives scaled, it is difficult to determine if the plan is accurate as the original planner
may have planned differently if the PTV1 was being treated to a total dose of 50.4 Gy with only
photons. The study was conducted with a small sample size, analyzing a wider variety of plans
14

with tumors in variable locations along the spinal canal may have yielded different results. Further
studies need to be conducted to evaluate whether the technique is more useful in a particular
location of the spine (cervical, thoracic, or lumbar).

Conclusion
The study indicated that the jaw-blocking VMAT technique was effective in lowering dose
to the spinal cord while maintaining acceptable coverage to target volumes. While dose increased
to OARs with the jaw-blocking VMAT technique, only the dose to the larynx was found to be
statistically significant.
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Table 1 Patient characteristics (n=7)
Patient
Age
Gender
1
47
Male
2
36
Female
3
40
Male
4
61
Male
5
51
Male
6
64
Male
7
32
Male
*Anonymized and randomized patient data
Figure 1. Beam arrangement for cervical spine plans

Figure 2. Beam arrangement for thoracic spine plans
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Diagnosis
C3 Chondrosarcoma
C2/C3 Chordoma
T3/T4 Chondrosarcoma
C5 Chondrosarcoma
C2 Chordoma
C1-C3 Chordoma
T10 Chondrosarcoma

Figure 3. Beam arrangement for thoracic spine plans vs tcervical spine plans

Figure 4. DVH Comparison of PTV, CTV, GTV, and Spinal Cord Dose
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